The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1083
ISSUE1083
July 24, 2000
Gemtuzumab for Relapsed Acute Myeloid Leukemia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Gemtuzumab for Relapsed Acute Myeloid Leukemia
July 24, 2000 (Issue: 1083)
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.